Last month in Redwood Shores, Calif., participants in the National Conference of Biotechnology Ventures decided to have some fun. Venture capitalists and biotech CEOs lined up to play a corporate version of "Family Feud," an old television game show in which competing families guessed at trivia.
 HIGH HOPES: Venture capitalists want functional genomics firms to partner with drug companies, says Karl Thiel. |
Their answer doesn't surprise investment analysts. "Every company having anything to do with genomics is now renaming itself a 'functional genomics' company," declares Stelios Papadopoulos, head of the health care investment banking group at PaineWebber Group Inc. in New York. He notes that a ...
